AstraZeneca U.S. trial data a confidence booster for COVID-19 shot
The drugmaker said on Monday that interim data from trials in Chile, Peru and the United States found the vaccine, developed in conjunction with Oxford University, was 79% effectiv…
The drugmaker said on Monday that interim data from trials in Chile, Peru and the United States found the vaccine, developed in conjunction with Oxford University, was 79% effectiv…